Dr. Xiaobing Qian joins Degron Therapeutics as Chief Development Officer

Shanghai, China and San Diego, CA, February 7, 2023, Degron Therapeutics Inc. announced today that X

By Degron,  Feb. 7, 2023 

Degron Therapeutics Co-Founder is invited to speak at the TPD meeting in San Diego

Dr. Yong Cang, CSO and Co-Founder of Degron Therapeutics, who has dedicated his research to the TPD

By Degron,  Dec. 6, 2022 

Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy

Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability

By Degron,  June 28, 2022,  

Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

SAN DIEGO, Calif., and SHANGHAI, China, June 9, 2022 - Degron Therapeutics (“Degron”), a biotechnolo

By Degron,  June 09,2022 

Degron Therapeutics Had an Exclusive Interview with CCTV2 "Economy 30 Minutes" Program

At 8:00 p.m. on March 11, 2022, the prime-time program “Economy 30 Minutes” on CCTV2 broadcast a spe

By Degron,  March 11, 2022 

The Theme Activities of "Degron Date" Concluded Successfully

With lush greens and pleasant weather, Shanghai headed into the best March spring. Degron empoyees g

By Degron, March 10, 2022 

Molecular Glue Degraders，a New Dawn Since PROTACs

Yong Cang, professor of ShanghaiTech University and co-founder of Degron Therapeutics

By Yong Cang,  August 18, 2020,